Anti-IL-12/23: The Next Big Thing in IBD?

被引：3

作者：

Schwartz, David ^{[1
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN 37203 USA

来源：

INFLAMMATORY BOWEL DISEASES | 2009年 / 15卷 / 12期

关键词：

INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; SEVERE CROHNS-DISEASE; RANDOMIZED-TRIAL; DOUBLE-BLIND; USTEKINUMAB; MAINTENANCE; ADALIMUMAB; INFLIXIMAB; PSORIASIS; EFFICACY;

D O I：

10.1002/ibd.20990

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1927 / 1928

页数：2

共 12 条

[1] A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease [J].

Burakoff, Robert ;

Barish, Charles F. ;

Riff, Dennis ;

Pruitt, Ronald ;

Chey, William Y. ;

Farraye, Francis A. ;

Shafran, Ira ;

Katz, Seymour ;

Krone, Charles L. ;

Vander Vliet, Martha ;

Stevens, Christopher ;

Sherman, Matthew L. ;

Jacobson, Eric ;

Bleday, Ronald .

INFLAMMATORY BOWEL DISEASES, 2006, 12 (07) :558-565

[2] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].

Colombel, Jean-Frederic ;

Sandborn, William J. ;

Rutgeerts, Paul ;

Enns, Robert ;

Hanauer, Stephen B. ;

Panaccione, Remo ;

Schreiber, Stefan ;

Byczkowski, Dan ;

Li, Ju ;

Kent, Jeffrey D. ;

Pollack, Paul F. .

GASTROENTEROLOGY, 2007, 132 (01) :52-65

[3] Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial [J].

Gottlieb, Alice ;

Menter, Alan ;

Mendelsohn, Alan ;

Shen, Yaung-Kaung ;

Li, Shu ;

Guzzo, Cynthia ;

Fretzin, Scott ;

Kunynetz, Rod ;

Kavanaugh, Arthur .

LANCET, 2009, 373 (9664) :633-640

[4] Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].

Hanauer, SB ;

Feagan, BG ;

Lichtenstein, GR ;

Mayer, LF ;

Schreiber, S ;

Colombel, JF ;

Rachmilewitz, D ;

Wolf, DC ;

Olson, A ;

Bao, WH ;

Rutgeerts, P .

LANCET, 2002, 359 (9317) :1541-1549

[5] The IL-23/IL-17 axis in inflammation [J].

Iwakura, Y ;

Ishigame, H .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (05) :1218-1222

[6]

Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4

[7] Anti-interleukin-12 antibody for active Crohn's disease [J].

Mannon, PJ ;

Fuss, IJ ;

Mayer, L ;

Elson, CO ;

Sandborn, WJ ;

Present, D ;

Dolin, B ;

Goodman, N ;

Groden, C ;

Hornung, RL ;

Quezado, M ;

Neurath, MF ;

Salfeld, J ;

Veldman, GM ;

Schwertschlag, U ;

Strober, W .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (20) :2069-2079

[8] Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) [J].

Papp, Kim A. ;

Langley, Richard G. ;

Lebwohl, Mark ;

Krueger, Gerald G. ;

Szapary, Philippe ;

Yeilding, Newman ;

Guzzo, Cynthia ;

Hsu, Ming-Chun ;

Wang, Yuhua ;

Li, Shu ;

Dooley, Lisa T. ;

Reich, Kristian .

LANCET, 2008, 371 (9625) :1675-1684

[9] Interleukin-12 and Th1 immune response in Crohn's disease: Pathogenetic relevance and therapeutic inplication [J].

Peluso, Ilaria ;

Pallone, Francesco ;

Monteleone, Giovanni .

WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (35) :5606-5610

[10] A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease [J].

Sandborn, William J. ;

Feagan, Brian G. ;

Fedorak, Richard N. ;

Scherl, Ellen ;

Fleisher, Mark R. ;

Katz, Seymour ;

Johanns, Jewel ;

Blank, Marion ;

Rutgeerts, Paul .

GASTROENTEROLOGY, 2008, 135 (04) :1130-1141

← 1 2 →